U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H17N7O5S3
Molecular Weight 471.534
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CEFMETAZOLE

SMILES

[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)CSCC#N)OC)C(O)=O

InChI

InChIKey=SNBUBQHDYVFSQF-HIFRSBDPSA-N
InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1

HIDE SMILES / InChI

Molecular Formula C15H17N7O5S3
Molecular Weight 471.534
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Cefmetazole is a semisynthetic cephamycin antibiotic. It has a broad spectrum of activity comparable to that of the second-generation cephalosporins, covering gram-positive, gram-negative, and anaerobic bacteria. Its bactericidal action results from inhibition of cell wall synthesis. It effectively treats abdominal and respiratory tract infections, pelvic inflammatory disease, urinary tract infections, skin and soft tissue infections and used for surgical prophylaxis, reducing or eliminating signs and symptoms of infection. Cefmetazole has a low frequency of adverse effects, and a side effect profile similar to that of other cephamycins. Adverse effects following overdosage have included nausea, vomiting, epigastric distress, diarrhea, and convulsions.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Cefmetazon
Curative
Cefmetazon
Curative
Cefmetazon
Curative
Cefmetazon
Curative
Cefmetazon

AUC

ValueDoseCo-administeredAnalytePopulation
151 μg × h/mL
1 g single, intravenous
CEFMETAZOLE plasma
Homo sapiens
301 μg × h/mL
2 g single, intravenous
CEFMETAZOLE plasma
Homo sapiens
83.1 μg × h/mL
0.5 g single, intravenous
CEFMETAZOLE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
1.43 h
1 g single, intravenous
CEFMETAZOLE plasma
Homo sapiens
1.3 h
2 g single, intravenous
CEFMETAZOLE plasma
Homo sapiens
1.5 h
0.5 g single, intravenous
CEFMETAZOLE plasma
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
2 g every 8-1 2 hours for 5-14 days
Route of Administration: Intravenous
In Vitro Use Guide
Cefmetazole is stable to any type of bacterial beta-lactamases, it inhibited growth of Escherichia coli carrying R plasmids, Klebsiella spp., Proteus vulgaris, and Bacteroides fragilis at the concentration of less than 0.78 to 25.0 ug/ml.
Substance Class Chemical
Record UNII
3J962UJT8H
Record Status Validated (UNII)
Record Version